Side-by-side · Research reference

MT-1vsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED9/51 cited

BPhase 2HUMAN-REVIEWED10/41 cited

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

MT-1

Retatrutide

Primary target

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

—

Origin

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

MT-1

Retatrutide

Standard dose

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Frequency

Every 60 days

Sustained release implant — no daily administration required.

Once weekly

Evidence basis

Phase 3 RCT / FDA-approved orphan drug

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Indication

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

—

Duration

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

Indefinite for chronic indication (presumed)

Route

Subcutaneous implant — upper arm or abdomen

—

Stability

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

—

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

Reconstitution

—

Investigational; not commercially available

Timing

—

Any time of day

Half-life

—

~6 days (estimated from class)

04Side Effects & Safety

Parameter

MT-1

Retatrutide

Nausea

Common (>10%) — mild, transient

—

Implant site reaction

Erythema, bruising, tenderness at insertion site

—

Hyperpigmentation

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

—

Melanocytic changes

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

—

Headache

Occasional (MC1R-independent melanocortin effects)

—

Photosensitivity (paradoxical)

Rare phototoxic reactions despite melanin increase

—

Contamination risk (unregulated)

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Pregnancy / OB

—

Avoid (insufficient data)

Absolute Contraindications

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

MT-1

Retatrutide

1. Implant insertion

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Site care

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Release kinetics

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

Once weekly, same day.

4. Repeat dosing

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

Refrigerate 2–8 °C. Light-protected.

5. Monitoring

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.

27–31G, 4–8 mm insulin syringe.